

No. BPPI/DRUG/RC-163/2021

Dated: 05/04/2022

ORDER

Bureau of Pharma Public Sector Undertakings of India, New Delhi now PMBI had published tender No. BPPI/DRUG/RC-163/2021 dated 18.03.2021 through e-procurement system for supply of drugs for the year 2021-23.

Whereas M/S Cosmas Research Lab Ltd. (here after called as the firm) addressed at Village Gaunspura, PO Noorpur Bet, Hambran, Ludhiana-141008 had participated in tender. The firm was awarded including DC- 1971, 1972 & 1976 by Bureau of Pharma Public Sector Undertakings of India, New Delhi now PMBI vide Letter of acceptance dated 30.09.2021 & 02.03.2022 for the period of 2 years as per tender provision. The firm was asked to supply the drugs within 45 days against purchase orders as per clause 19 (D) of tender document as per details below: -

S.No.	BPPI purchase order No and Date	Drug Code and Name	Quantity Ordered	Delivery Period	Quantity Pending for supply
1	2102000086 dated 13.04.2021	1 Aceclofenac 100mg and Paracetamol 325mg Tablets	400000	45 Days (Expired on 28.05.2021)	400000
2	2102000085 dated 13.4.2021	1 Aceclofenac 100mg and Paracetamol 325mg Tablets	200000	45 Days (Expired on 28.05.2021)	200000
3	2002002298 dated 12.02.2021	92 Doxycycline Capsules IP 100mg	50000	45 Days (Expired on 29.03.2021)	50000
4	2002002297 dated 12.02.2021	92 Doxycycline Capsules IP 100mg	14000	45 Days (Expired on 29.03.2021)	14000
5	2002001353 dated 09.11.2020	429 Atorvastatin and Fenofibrate Tablets (10mg+160mg)	100000	45 Days (Expired on 24.12.2020)	100000
6	2002001648 dated 06.01.2021	360 Mifepristone Tablets IP 200 mg	5000	45 Days (Expired on 20.02.2021)	5000

Whereas Pharmaceuticals & Medical Devices Bureau of India, New Delhi sent show cause notice vide reference No. BPPI/DRUG/RC-163/2021 to M/S Cosmas Research Lab Ltd. through mail/DAK dated 22.03.2022 asking for explanation informing about provisions of the clause no. 19(G), 26(H), 27(A) and 27(E) of tender document with request to supply of goods.

Ravi Indhu

Page 1 | 2

- (i) Consider bad performance for future dealings and disqualify your company from participating in the tender for the next 2 years.
- (ii) Recover 5% value of supply order from pending bills.
- (iii) Initiate blacklisting of your company.

Whereas the M/S Cosmas Research Lab Ltd. replied against show cause notice on dated 30.03.2022 through mail wherein vendor informed that due to API raw material price increased hence M/S Cosmas Research Lab Ltd. unable to supply above mentioned Purchase orders and asking to withdraw of the quoted products. Therefore, as per clause 27 (A) 5% of total Plan quantity of LOA quantities Performance Security Deposit of Rs. 3521250/- shall be recovered from M/S Cosmas Research Lab Ltd.

In view of above, the firm is blacklisted for a period of two (02) successive years to participate in the tender of **Pharmaceuticals & Medical Devices Bureau of India, New Delhi** for supply of all drugs/products from date of issuance of this order.

This order is without prejudice to the legal and criminal action to be taken if any, by Pharmaceuticals & Medical Devices Bureau of India, New Delhi in the matter.



Ravi Dadhich, DANICS
Chief Executive Officer
Pharmaceuticals & Medical Devices Bureau of India, New Delhi

Regd.
To,
M/S Cosmos Research Lab Ltd.
Village Gaunspura, PO Noorpur Bet,
Hambran, Ludhiana-141008